Emma Bendana, MD
Urology · Las Cruces, NMNPI 1235303512
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Boston Scientific at 54.9% of the total. Reporting peaked in 2023 at $9,995 and has fallen 73.4% since, to $2,660 in 2025. Among urology clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $68.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$10K
- Axonics, Inc.$2K
- Procept Biorobotics Corporation$1K
- Siemens Medical Solutions USA, Inc.$765
- Teleflex LLC$603
- Calyxo, Inc.$476
- plus $3K from 33 others
What the payments were for
- Consulting fees$5,80032%
- Travel & lodging$3,98222%
- Food & beverage$8,12745%
- Education$2181%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 68 | $9,944 |
| Axonics, Inc. | 61 | $1,936 |
| Procept Biorobotics Corporation | 5 | $1,416 |
| Siemens Medical Solutions USA, Inc. | 3 | $765 |
| Teleflex LLC | 9 | $603 |
| Calyxo, Inc. | 10 | $476 |
| Astellas Pharma US Inc | 15 | $397 |
| GE HealthCare | 3 | $327 |
| Merck | 9 | $218 |
| AbbVie(2 entities) | 10 | $205 |
| Pfizer | 11 | $200 |
| Sumitomo Pharma America, Inc. | 8 | $165 |
| Caldera Medical, Inc | 4 | $141 |
| Progenics Pharmaceuticals, Inc. | 3 | $135 |
| Myriad Genetic Laboratories, Inc. | 3 | $134 |
| Laborie Medical Technologies Corp. | 3 | $127 |
| Amgen | 6 | $111 |
| Olympus America Inc. | 4 | $100 |
| Bayer | 2 | $99 |
| Urogen Pharma, Inc. | 3 | $95 |
| Johnson & Johnson | 4 | $79 |
| Abbott | 1 | $58 |
| Novartis | 2 | $57 |
| Medtronic | 2 | $36 |
| Myovant Sciences Inc. | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| 180 Medical, Inc. | 1 | $26 |
| Coloplast | 1 | $23 |
| Agiliti Surgical, Inc. | 1 | $23 |
| RGH Enterprises LLC | 1 | $22 |
| Dendreon Pharmaceuticals LLC | 1 | $22 |
| Blue Earth Diagnostics | 1 | $20 |
| Sanofi | 1 | $18 |
| Tolmar, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Richard Wolf Medical Instruments Corp. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$1,226
- Uroskop Omnia Max$721
- Bulkamid$402
- Axonics$402
- Moses 550 D\F\L$254
- UroLift System$245
- Lumenis Pulse 120H$208
- GENERAL KIDNEY STONE DISEASE$168
- Axonics r-SNM System$161
- LithoVue$135
- CVAC Aspiration System$135
- GENERAL ERECTILE DYSFUNCTION$132
- GENERAL BPH$114
- myRisk$104
How this compares
$18,127 in reported general payments places this provider in the 90th percentile of 46 urology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 108 | $107,530 |
| GemtesaVibegron | 13 | $14,401 |
| Solifenacin Succinate | 137 | $6,859 |
| Mirabegron ErMirabegron | 11 | $6,607 |
| Tamsulosin Hcl | 272 | $4,945 |
| Cephalexin | 158 | $2,411 |
| Trospium Chloride | 30 | $1,865 |
| NitrofurantoinNitrofurantoin Macrocrystal | 40 | $1,658 |
| Estradiol | 17 | $1,138 |
| Finasteride | 84 | $1,049 |
| Oxybutynin Chloride ErOxybutynin Chloride | 59 | $1,003 |
| Tolterodine Tartrate | 18 | $935 |
| Oxybutynin Chloride | 55 | $895 |
| Testosterone | 11 | $793 |
| Doxazosin Mesylate | 58 | $774 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $397 | $107,530108 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $165 | $14,40113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 46 urology providers in New Mexico.
Other urology in Las Cruces
- Robert KolosseusLas Cruces$5K
- Thomas GormleyLas Cruces$5K
- Mark BieriLas Cruces$104
- Benjamin MontgomeryLovington$166K
- Wayne KuangAlbuquerque$128K
- Jordan ForemanAlbuquerque$60K
- Andrew GrollmanAlbuquerque$16K
- Aaron GeswaldoAlbuquerque$11K
- Jonathan NelsonAlbuquerque$6K
- Stefan GutowAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.